@article {van der Velden2021.02.27.21251952, author = {Peter G. van der Velden and Miquelle Marchand and Marcel Das and Ruud Muffels and Mark Bosmans}, title = {The prevalence, incidence and risk factors of mental health problems and mental health services use before and 9 months after the COVID-19 outbreak among the general Dutch population. A 3-wave prospective study}, elocation-id = {2021.02.27.21251952}, year = {2021}, doi = {10.1101/2021.02.27.21251952}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Objectives Gain insight in the effects of the COVID-19 pandemic on the prevalence, the incidence and risk factors of mental health problems among the Dutch general population and different age groups in November-December 2020, compared to the prevalence, incidence, and risk factors in the same period in 2018 and 2019. More specifically, the prevalence, incidence and risk factors of anxiety and depression symptoms, sleep problems, fatigue, disabilities due to health problems, use of medicines for sleep problems, medicines for anxiety and depression, and mental health services use.Methods We extracted data from the LISS (Longitudinal Internet studies for the Social Sciences) panel that is based a probability sample of the Dutch population of 16 years and older by Statistics Netherlands. We used three waves of the longitudinal Health module held in November-December 2018 (T1), November-December 2019 (T2) and November-December 2020 (T3), and selected respondents who were 18 years and older at T1. Data were weighted using 16 demographics profiles of the Dutch adult population (Nstudy sample=4,064). The course of mental health problems was examined with repeated measures multivariate logistic regression analyses, and the differences in incidence with multivariate logistic regression analyses. In both types of analyses, we controlled for sex, age, marital status, employment status, education level and physical disease.Results The repeated measures multivariate logistic regression analyses among the total study sample did not reveal a significant increase in the prevalence of anxiety and depression symptoms, sleep problems, fatigue, disabilities due to health problems, use of medicines for sleep problems, medicines for anxiety and depression, and mental health services use in November- December 2020, compared to November-December 2018 and 2019 (that is, T3 did not differ from T1 and T2). Among the four different age categories (18-34, 35-49, 50-64, and 65 years old and older respondents), 50-64 years respondents had a significantly lower prevalence of anxiety and depression symptoms at T3 than at T1 and T2, while T1 and T2 did not differ. A similar pattern among 65+ respondents was found for mental health services use. We found no indications that the incidence of examined health problems at T2 (no problem at T1, problem at T2) and T3 (no problem at T2, problem at T3) differed. Risk factors for mental health problems at T2 were mostly similar to risk factors at T3; sex and age were less associated with sleep problems at T3, compared to T2 .Conclusions The prevalence, incidence and risk factors of examined mental health problems examined nine months after the COVID-19 outbreak appear to be very stable across the end of 2018, 2019 and 2020 among the Dutch adult population and different age categories, suggesting that the Dutch adult population (20 years and older) in general is rather resilient given all disruptions due to this pandemic.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialnot applicableFunding StatementNo external funding receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB. According to the Dutch Medical Research Involving Human Subjects Act (WMO) the present study did not require approval from a Medical Ethical Testing Committee (METC). Nevertheless, the longitudinal Health module (as part of the Longitudinal Core Study in LISS, starting in 2007) were evaluated and approved by the Board of Overseers, an Internal Review Board (IRB) until 2014. In accordance with the General Data Protection Regulation (GDPR), participants gave explicit written consent for the use of the collected data for scientific and policy relevant research. The LISS panel has received the international Data Seal of Approval (see https://www.datasealofapproval.org/en/). All data of studies conducted with the LISS panel are anonymized. OPEN ACCESS. The data of the LISS panel are open access for researchers and policy makers. Further information about the regulations for free access to the data can be found at https://www.dataarchive.lissdata.nl. Access to the data was granted after registration.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study was conducted using the Dutch Longitudinal Internet studies for the Social Sciences (LISS) panel. Further information about all conducted surveys and regulations for free access to the data can be found at https://www.dataarchive.lissdata.nl/ (in English). The LISS panel has received the international Data Seal of Approval (see https://www.datasealofapproval.org/en/). All data of studies conducted with the LISS panel are anonymized. For this study we used the open access data of the Health module (see https://www.dataarchive.lissdata.nl/study_units/view/12, wave 11, 12 and 13). https://www.dataarchive.lissdata.nl/}, URL = {https://www.medrxiv.org/content/early/2021/03/02/2021.02.27.21251952}, eprint = {https://www.medrxiv.org/content/early/2021/03/02/2021.02.27.21251952.full.pdf}, journal = {medRxiv} }